VERACYTE INC

Insightful insider sales reveal McGuire Annie’s disciplined approach and growing confidence in Veracyte’s oncology‑diagnostics growth prospects.

Veracyte insider Robert Epstein sells 10,000 shares at $44.01— a disciplined, rule‑based move that signals neutral investor sentiment while the company continues its oncology growth.

Veracyte insider sale: General Counsel Annie McGuire sells 10,204 shares under 10(b)(5) plan amid 22‑24% price rise—what it signals for investors.

Veracyte insiders boost confidence with fresh share purchases amid a strong pipeline and rising stock, signaling leadership’s bullish outlook.

Insider sales at Veracyte show steady, small trades—like the latest 6,902‑share sale by General Counsel Annie McGuire—indicating stable confidence while the company’s P/E and biotech pipeline suggest growth prospects remain intact.